« Return to News | R&D Trends

NeuroSigma awarded $680,000 NIH grant for TFN-covered stent

Monday, April 9, 2012 10:39 AM

NeuroSigma, a Los Angeles-based medical device company, has been awarded a phase I NIH-STTR grant from the National Institute of Neurological Disorders and Stroke (NINDS) for the further development of its Thin-Film Nitinol (TFN)-covered stent for the potential treatment of brain aneurysms. 

The phase I grant, totaling approximately $680,000 (two tranches), extends over a period of more than a year, with the second tranche of funding subject to the availability of funds and satisfactory progress made using the first tranche. The NINDS STTR program may provide up to an additional $3 million of follow-on phase II funding for additional clinical studies.

The major focus of the project is further development and pre-clinical testing of NeuroSigma's TFN-covered stent for the potential treatment of brain aneurysms. The TFN-covered stent technology was developed at the University of California, Los Angeles (UCLA) and is exclusively licensed by UCLA to NSVascular, a majority-owned subsidiary of NeuroSigma. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat. 

NSVascular will initially focus on developing and commercializing TFN-covered stents for endovascular applications, with its first two applications being flow-diverting stents for intracranial aneurysms and stents for treating peripheral artery disease.

Mayo Clinic is the sponsored research institution in this STTR grant.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.